Novavax (NVAX) Profit Jumps on Milestone
(NASDAQ:NVAX), known for its protein-based vaccine technology, released its second quarter fiscal 2025 results on August 6, 2025. The standout news was a return to profitability on a GAAP basis, driven by significant partnership milestone payments, most notably a $175 million payment linked to U.S. regulatory approval of its COVID-19 vaccine. Revenue (GAAP) reached $239 million, ahead of analyst expectations of $152.61 million, while diluted earnings per share (GAAP) came in at $0.62, well above the expected loss of $0.04. While the company beat expectations decisively, its business model is in transition, with product sales falling sharply and partnership revenues comprising the bulk of results this period.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Novavax is a biotechnology company specializing in the development of recombinant protein-based vaccines, including its COVID-19 shot and the adjuvant Matrix-M, which enhances immune responses. Its core offering, Nuvaxovid, is the only recombinant protein-based, non-messenger RNA (mRNA) COVID-19 vaccine currently available in the U.S.
Source Fool.com
Novavax Inc. Aktie
Durchaus positiv bewertet unsere Community derzeit Novavax Inc. mit 10 Buy-Einschätzungen und 2 Sell-Einschätzungen.
Mit einem Kursziel von 18 € für Novavax Inc. zeigt sich ein beachtliches Wachstumspotenzial gegenüber dem aktuellen Kurs von 8.3 €.
